Please reload

Recent Posts

CreaGen & C2I's CEO/Co-founder Recieves 2018 Henry A. Hill Award

November 26, 2018

Please reload

Featured Posts

Welcome to C2I's newest tenants: SynerK, Inc.

February 19, 2019

 We would like to extend a warm welcome to the newest members of the C2I family.


SynerK, Inc. is a biotechnology company engaged in the development of life changing treatment in the areas of cancer, inflammatory and rare diseases. SynerK utilizes antisense technology to specifically silence genes that are responsible for various diseases.


Please reload

Follow Us